Literature DB >> 7958931

Multiple regions of TBP participate in the response to transcriptional activators in vivo.

W P Tansey1, S Ruppert, R Tjian, W Herr.   

Abstract

We used mutant yeast and human TBP molecules with an altered DNA-binding specificity to examine the role of TBP in transcriptional activation in vivo. We show that yeast TBP is functionally equivalent to human TBP for response to numerous transcriptional activators in human cells, including those that do not function in yeast. Despite the extensive conservation of TBP, its ability to respond to transcriptional activators in vivo is curiously resistant to clustered sets of alanine substitution mutations in different regions of the protein, including those that disrupt DNA binding and basal transcription in vitro. Combined sets of these mutations, however, can attenuate the in vivo activity of TBP and can differentially affect response to different activation domains. Although the activity of TBP mutants in vivo did not correlate with DNA binding or basal transcription in vitro, it did correlate with binding in vitro to the largest subunit of TFIID, hTAFII250. Together, these data suggest that TBP utilizes multiple interactions across its surface to respond to RNA polymerase II transcriptional activators in vivo; some of these interactions appear to involve recruitment of TBP into TFIID, whereas others are involved in response to specific types of transcriptional activators.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7958931     DOI: 10.1101/gad.8.22.2756

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  26 in total

1.  Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner.

Authors:  C Suñé; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

2.  Requirement for transcription factor IIA (TFIIA)-TFIID recruitment by an activator depends on promoter structure and template competition.

Authors:  P M Lieberman; J Ozer; D B Gürsel
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

3.  pX, the HBV-encoded coactivator, suppresses the phenotypes of TBP and TAFII250 mutants.

Authors:  I Haviv; Y Matza; Y Shaul
Journal:  Genes Dev       Date:  1998-04-15       Impact factor: 11.361

4.  Polymerase (Pol) III TATA box-binding protein (TBP)-associated factor Brf binds to a surface on TBP also required for activated Pol II transcription.

Authors:  Y Shen; G A Kassavetis; G O Bryant; A J Berk
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

5.  Mutations in the carboxy-terminal domain of TBP affect the synthesis of human immunodeficiency virus type 1 full-length and short transcripts similarly.

Authors:  P S Pendergrast; D Morrison; W P Tansey; N Hernandez
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  The large subunit of basal transcription factor SNAPc is a Myb domain protein that interacts with Oct-1.

Authors:  M W Wong; R W Henry; B Ma; R Kobayashi; N Klages; P Matthias; M Strubin; N Hernandez
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

7.  CTF5--a new transcriptional activator of the NFI/CTF family.

Authors:  S Wenzelides; H Altmann; W Wendler; E L Winnacker
Journal:  Nucleic Acids Res       Date:  1996-06-15       Impact factor: 16.971

8.  Stepwise recruitment of components of the preinitiation complex by upstream activators in vivo.

Authors:  S He; S J Weintraub
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

9.  Direct stimulation of transcription by negative cofactor 2 (NC2) through TATA-binding protein (TBP).

Authors:  Yong Cang; Gregory Prelich
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-17       Impact factor: 11.205

10.  The ability to associate with activation domains in vitro is not required for the TATA box-binding protein to support activated transcription in vivo.

Authors:  W P Tansey; W Herr
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.